COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2017-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/195 |
| _version_ | 1797878937406144512 |
|---|---|
| author | N. L. Pogudina E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov |
| author_facet | N. L. Pogudina E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov |
| author_sort | N. L. Pogudina |
| collection | DOAJ |
| description | Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. |
| first_indexed | 2024-04-10T02:39:56Z |
| format | Article |
| id | doaj.art-510e92d40fef4d478021f3c82e9a7a72 |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:39:56Z |
| publishDate | 2017-08-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-510e92d40fef4d478021f3c82e9a7a722023-03-13T07:48:15ZrusIRBIS LLCФармакоэкономика2070-49092070-49332017-08-01102122110.17749/2070-4909.2017.10.2.012-021172COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMAN. L. Pogudina0E. G. Kosolapov1F. S. Kochenkov2A. V. Karaulov3N. L. Bondarenko4D. V. Blinov5Independent Research Company «Smart Choice»Independent Research Company «Smart Choice»Independent Research Company «Smart Choice»I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian FederationI.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation; Clinical Hospital № 85, FMBA of RussiaN. I. Pirogov Russian National Research Medical UniversityComparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.https://www.pharmacoeconomics.ru/jour/article/view/195asthmainhaled corticosteroidsicslong-acting beta agonistslabavilanterolfluticasone furoatebudesonideformoterolfixed-dose combinationcost-minimization analysisbudget impact analysis |
| spellingShingle | N. L. Pogudina E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA Фармакоэкономика asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis |
| title | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
| title_full | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
| title_fullStr | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
| title_full_unstemmed | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
| title_short | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
| title_sort | comparative cost minimization and budget impact analysis of fixed dose inhaled corticosteroid long acting betaagonist combinations in the treatment of asthma |
| topic | asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis |
| url | https://www.pharmacoeconomics.ru/jour/article/view/195 |
| work_keys_str_mv | AT nlpogudina comparativecostminimizationandbudgetimpactanalysisoffixeddoseinhaledcorticosteroidlongactingbetaagonistcombinationsinthetreatmentofasthma AT egkosolapov comparativecostminimizationandbudgetimpactanalysisoffixeddoseinhaledcorticosteroidlongactingbetaagonistcombinationsinthetreatmentofasthma AT fskochenkov comparativecostminimizationandbudgetimpactanalysisoffixeddoseinhaledcorticosteroidlongactingbetaagonistcombinationsinthetreatmentofasthma AT avkaraulov comparativecostminimizationandbudgetimpactanalysisoffixeddoseinhaledcorticosteroidlongactingbetaagonistcombinationsinthetreatmentofasthma AT nlbondarenko comparativecostminimizationandbudgetimpactanalysisoffixeddoseinhaledcorticosteroidlongactingbetaagonistcombinationsinthetreatmentofasthma AT dvblinov comparativecostminimizationandbudgetimpactanalysisoffixeddoseinhaledcorticosteroidlongactingbetaagonistcombinationsinthetreatmentofasthma |